PC-3/PC-3/PC-3/人前列腺癌细胞

PC-3/PC-3细胞系/PC-3细胞株/PC-3人前列腺癌细胞

Cell line name PC-3

Synonyms PC3; PC.3

Accession CVCL_0035

Resource Identification Initiative To cite this cell line use: PC-3 (RRID:CVCL_0035)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: JFCR39 cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

Part of: NCI-60 cancer cell line panel.

Population: Caucasian.

Doubling time: 25.34 +- 0.02 hours (PubMed=32968452); 25 hours (ATCC=CRL-7934); 40 +- 10 hours (CLS=300312); ~50 hours (DSMZ=ACC-465); 27.1 hours (NCI-DTP=PC-3); ~25 hours (PBCF).

Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: Glycoproteome analysis by proteomics.

Omics: GPI-anchored proteins analysis by proteomics.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427.

Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.

PubMed=9460501; DOI=10.1016/S0165-4608(97)00060-5

Nupponen N.N., Hyytinen E.R., Kallioniemi A.H., Visakorpi T.

Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.

Cancer Genet. Cytogenet. 101:53-57(1998)

 

PubMed=9823299

Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.

Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.

Cancer Res. 58:5009-5013(1998)

 

PubMed=10702678; DOI=10.1159/000015432

Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.N., Isola J.J., Visakorpi T., Bergerheim U.S.R., Larsson C.

Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.

Cytogenet. Cell Genet. 87:225-232(1999)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H

Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N.

Role of antioxidant systems in human androgen-independent prostate cancer cells.

Prostate 43:144-149(2000)

 

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H

Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Mol. Carcinog. 28:236-246(2000)

 

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E

Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.

IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.

Genes Chromosomes Cancer 30:143-160(2001)

 

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3

Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.

The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.

Cancer Genet. Cytogenet. 124:112-121(2001)

 

PubMed=11304728; DOI=10.1002/pros.1045

van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.

Widely used prostate carcinoma cell lines share common origins.

Prostate 47:36-51(2001)

 

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

 

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

 

PubMed=12606952; DOI=10.1038/sj.onc.1206247

Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.

Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.

Oncogene 22:1247-1252(2003)

 

PubMed=12725112; DOI=10.1385/1-59259-372-0:21

Russell P.J., Kingsley E.A.

Human prostate cancer cell lines.

Methods Mol. Med. 81:21-39(2003)